☆ 4.2 Meeting Abstract

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 23, Issue -, Pages S461-S461

Publisher

CIG MEDIA GROUP, LP

Keywords

MCL; VIPOR; targeted therapy in lymphoma; circulating tumor DNA; minimal residual disease

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.